Genelux initiated with a Buy at Lake Street

Lake Street analyst Chad Messer initiated coverage of Genelux (GNLX) with a Buy rating and $16 price target The pivotal readout for olvimulogene nanivacirepvec, or olvi-vec, in ovarian cancer, due in the first half of 2026, could “revolutionize treatment of this deadly indication,” the analyst tells investors. The firm forecasts peak U.S. sales of $2B in this indication alone, but also notes two more shots on goal in lung cancer that it contends “could boost strategic interest.”